GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics ...

PISCATAWAY, N.J., Aug. 27, 2024 /PRNewswire/ -- Legend Biotech (LEGN), a subsidiary of GenScript Biotech Corporation (hereinafter referred to as "GenScript"), a global leader in life sciences research ...

R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...

GenScript announced the official opening of its first European mRNA production site in Delft, the Netherlands, marking a significant expansion of the company's global mRNA platform and reinforcing ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation ...

PISCATAWAY, N.J., March 12, 2024 /PRNewswire/ -- On March 11, 2024, GenScript Biotech Corporation (HK.1548), a world's leading technology and service provider of life science R&D and manufacturing, ...

As of December 31, 2023, 88,700 peer-reviewed journal articles worldwide had cited GenScript 's services and products. Guided by its mission to make people and nature healthier through biotechnology, ...

PISCATAWAY, N.J., July 9, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that it has been ...

PISCATAWAY, N.J., Aug. 17, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global pioneer in life sciences innovation, today announced outstanding interim results for the first half of ...

Jefferies analyst Chris Lui maintained a Buy rating on Genscript Biotech (GNNSF – Research Report) on December 21 and set a price target of HK$30.00. The company’s shares closed last Tuesday at $2.65.

Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...